ANAVEX LIFE SCIENCES CORP. (AVXL)
ANAVEX LIFE SCIENCES CORP. (AVXL)
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss and comprehensive loss | -5,681 | -9,827 | -36,550 |
| Share based compensation | 1,107 | 3,721 | 7,828 |
| Incentive and tax receivables | 35 | -11 | -1,629 |
| Prepaid expenses and deposits | -33 | -19 | -483 |
| Accounts payable | -1,610 | -2,491 | -2,887 |
| Gain on settlement of accounts payable | NaN | NaN | 0 |
| Accrued liabilities | -965 | -37 | -906 |
| Deferred grant income | NaN | 0 | 37 |
| Net cash used in operating activities | -7,151 | -8,604 | -30,440 |
| Issuance of common shares, net of share issue costs | 36,323 | 9,198 | NaN |
| Payment for taxes related to cashless exercise of options | NaN | 2,707 | NaN |
| Proceeds from exercise of stock options | NaN | 1,264 | 1,679 |
| Payment for taxes related to cashless exercise of options | NaN | NaN | -2,262 |
| Issuance of common shares | NaN | NaN | 0 |
| Net cash provided by financing activities | 36,323 | 10,017 | -583 |
| (decrease) increase in cash and cash equivalents during the period | 29,172 | 1,413 | -31,023 |
| Cash and cash equivalents at beginning of period | 102,577 | 132,187 | NaN |
| Cash and cash equivalents at end of period | 131,749 | 102,577 | NaN |